- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05611164
Evaluation of SiD's System for Improving Assisted Reproduction Treatments
SiD, an Assistant for Sperm Selection During Intracytoplasmic Sperm Injection in Medically Assisted Reproduction: Effect on Fertilization, Blastocyst Formation, Early Pregnancy Loss, and Consistent Practice. A Prospective Pilot Study.
According to the WHO, infertility affects 15% of reproductive age couples worldwide. Among the assisted reproductive technologies available for patients with infertility, intracytoplasmic sperm injection (ICSI) has become one of the most widely employed and is now thought to be the most common method for oocyte insemination outside of the human body.
ICSI entails the selection of an individual sperm cell and its injection directly into an oocyte. Usually, an embryologist performs the selection of the individual sperm cell to inject by subjectively observing the morphology and progression of the candidate spermatozoon. Subjectivity and time constrains, however, suggest the best possible candidate might not always be selected. Further optimization of ICSI technology remains a significant goal, yet the majority of approaches proposed in the literature have returned mixed results. The deployment of an artificial intelligence (AI) software capable of detecting and non-invasively predicting the value of individual spermatozoa in real time could significantly improve ICSI.
SiD (IVF 2.0 Ltd, London, UK) is a software designed to identify, evaluate, and assist in the spermatozoon selection process ahead of ICSI. SID uses a mathematical model to evaluate individual spermatozoa in real-time according to their motility patterns (for instance velocity, linearity, straightness) and their morphology. The software has been developed by making use of retrospective data analysis, but its prospective evaluation is still pending.
With the above in mind, this study intends to address the following question: can the use of a software assistant for the selection of individual sperm cells for injection (SiD), improve ICSI outcomes (oocyte fertilization, embryo development and quality, embryo ploidy, pregnancy, and live birth)? Patients with a clinical indication for undergoing ICSI will be prospectively enrolled into the study. Following ovarian stimulation, the oocytes retrieved from each patient will be randomly split into two groups and inseminated by ICSI using sperm selected either subjectively by an embryologist (control group) or by the software assistant SiD (experimental group). Embryos will be allowed to develop for up to six days and until blastocyst formation assessments are completed. Embryos might be subjected to cytogenetic screening or used for embryo transfer according to patient needs. The recorded outcomes will be anonymized prior to statistical analysis.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Mexico City, Mexico, 11000
- New Hope Fertility Center
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44630
- New Hope Fertility Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant's age between 18 and 40 years of age.
- Informed consent signed by the patient before treatment.
- IVF treatments with medical or embryology indication to perform ICSI.
- Cycles with at least 2 oocytes in Metaphase II.
- Fresh ejaculated motile sperm.
- Fresh oocytes.
- Selection of sperm using a 7% or 10% PVP solution.
- Presence of motile sperm at the time of sperm selection for ICSI.
- Videos recorded with a total magnification of 200x.
Exclusion Criteria:
- Patients diagnosed with recurrent pregnancy loss.
- Spermatozoa extracted by testicular biopsy.
- Frozen/thawed spermatozoa.
- Frozen/thawed oocytes in any case.
- That the recommendations for use of SiD have not been fully followed.
- Poor quality of saved ICSI video.
- Inability to reliably trace sperm-oocyte-embryo throughout the process.
- Oocytes that are not in Metaphase II.
- Patients with immotile sperm
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Sperm selected by embryologist without software assistance
For each patient, oocytes collected following one ovarian stimulation cycle are randomly distributed in two groups ("no intervention" and "experimental" arms), in a sibling oocyte study design.
In the "no intervention" arm, the individual spermatozoa for injection are selected subjectively by the embryologist.
|
|
Experimental: Sperm selected with AI assistant SiD
For each patient, oocytes collected following one ovarian stimulation cycle are randomly distributed in two groups ("no intervention" and "experimental" arms), in a sibling oocyte study design.
In the "experimental" arm, the spermatozoa selection for injection is performed based on the recommendation of the AI assistant SiD.
|
Half of the oocytes will be injected with a sperm selected with SiD's assistance
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fertilization rate
Time Frame: 16-18 hours after ICSI
|
Rate of oocytes that present two pronuclei or cell division
|
16-18 hours after ICSI
|
Blastocyst formation rate
Time Frame: around 120 hours after ICSI
|
Rate of oocytes that have a defined trophectoderm and inner cell mass
|
around 120 hours after ICSI
|
Usable blastocyst formation rate
Time Frame: around 120 hours after ICSI
|
Rate of oocytes that have a blastocyst that is transferable accoring to its quality
|
around 120 hours after ICSI
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ploidy status
Time Frame: trophectoderm biopsy is performed around 120 hours after ICSI
|
euploid rate (when available)
|
trophectoderm biopsy is performed around 120 hours after ICSI
|
Biochemical pregnancy
Time Frame: 2 weeks after blastocyst transference
|
human beta chorionic gonadotropin
|
2 weeks after blastocyst transference
|
Clinical pregnancy
Time Frame: 6 weeks after blastocyst transference
|
Presence of heartbeat
|
6 weeks after blastocyst transference
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P002-SP002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infertility
-
Assuta Hospital SystemsMaccabi Healthcare Services, IsraelCompletedInfertility, Female Infertility, Male InfertilityIsrael
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedPregnancy | Male Infertility | Female InfertilityNetherlands
-
Sapientiae InstituteTerminated
-
Esraa Gamal AhmedAin Shams Maternity HospitalUnknownUnexplained Female Infertility
-
King's College LondonNot yet recruitingInfertility | Infertility, Female | Infertility Unexplained | Infertility of Tubal Origin
-
Gazi UniversityCompletedMale Infertility | Unexplained Infertility
-
Wake Forest University Health SciencesWithdrawnUterine Diseases | Endometriosis | Infertility Unexplained | Endometrial Diseases | Infertility; Female, NonimplantationUnited States
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMale Infertility, AzoospermiaUnited States
-
Pacific Fertility CenterTerminatedPrimary Female Infertility | Secondary Female Infertility
-
Istanbul University - Cerrahpasa (IUC)RecruitingInfertility | Sexual Dysfunction | Infertility, Male | Nurse's Role | Sexuality | Infertility; FemaleTurkey